Granted Patent B2

US 12,582,608 · App. 17/593,437 · Granted Mar 24, 2026

Inventors: Rosemary Kanasty (Cambridge, MA); Tyler Grant (Arlington, MA); Erick Peeke (Cambridge, MA); Nupura Bhise (Watertown, MA); David Altreuter (Watertown, MA); Sonia Holar (Watertown, MA); Marlene Schwarz (Watertown, MA)

Assignee: NORTIVA BIO, INC.

A61K9/4891A61K9/4833A61K9/485A61K9/4858A61K9/4866A61K45/06

Abstract

Claims (22)

1 . An enrobed gastric residence dosage form comprising:

a gastric residence system in a folded configuration; and

a first coating enrobing the gastric residence system in the folded configuration; and

a second coating on the first coating enrobing the gastric residence system in the folded configuration, wherein the first coating and the second coating do no comprise a therapeutic agent, and

wherein the enrobed gastric residence dosage form is configured to release the gastric residence system in a stomach of a patient, allowing the gastric residence system to assume an open configuration.

2 . The enrobed gastric residence dosage form of claim 1 , wherein a thickness of the first coating enrobing the gastric residence system in the folded configuration is from 50 to 250 microns.

3 . The enrobed gastric residence dosage form of claim 1 , wherein the first coating enrobing the gastric residence system in the folded configuration is applied to the gastric residence system in the folded configuration using a rotary die encapsulation process.

4 . The enrobed gastric residence dosage form of claim 1 , wherein the first coating enrobing the gastric residence system in the folded configuration comprises a softgel type shell material.

5 . The enrobed gastric residence dosage form of claim 1 , wherein the first coating enrobing the gastric residence system in the folded configuration provides a hermetic seal.

6 . The enrobed gastric residence dosage form of claim 1 , wherein the first coating enrobing the gastric residence system in the folded configuration comprises from 5 to 10 wt. % water.

7 . The enrobed gastric residence dosage form of claim 1 , wherein the first coating enrobing the gastric residence system in the folded configuration comprises from 20 to 60 wt. % one or more of glycerin or sorbitol.

8 . The enrobed gastric residence dosage form of claim 1 , wherein the first coating enrobing the gastric residence system in the folded configuration comprises from 35 to 75 wt. % one or more of gelatin, pullulan, hydroxypropyl methylcellulose, or potato starch.

9 . The enrobed gastric residence dosage form of claim 1 , wherein the first coating enrobing the gastric residence system in the folded configuration comprises from 10 to 50 wt. % a polymethacrylate-based polymer.

10 . The enrobed gastric residence dosage form of claim 1 , comprising a sleeve, wherein the sleeve surrounds at least a portion of the gastric residence system in the folded configuration, wherein the sleeve comprises at least one of gelatin, hydroxypropyl methylcellulose, or pullulan.

11 . The enrobed gastric residence dosage form of claim 1 , comprising a capsule encapsulating the gastric residence system in the folded configuration, wherein the capsule comprises at least one of gelatin, hydroxypropyl methylcellulose, or pullulan.

12 . The enrobed gastric residence dosage form of claim 1 , wherein the second coating on the first coating enrobing the gastric residence system comprises a polymethacrylate-based polymer.

13 . The enrobed gastric residence dosage form of claim 1 , wherein the second coating on the first coating enrobing the gastric residence system comprises an anti-tacking agent comprising at least one of talc or magnesium stearate.

14 . The enrobed gastric residence dosage form of claim 1 , wherein the second coating on the first coating enrobing the gastric residence system comprises a plasticizer comprising at least one of a phthalate, a phosphate, a citrate, a tartrate, an adipate, a sebacate, a sulfonamide, a succinate, a glycolate, a glycerolate, a benzoate, a myristate, a halogenated phenyl, a poloxamer, triacetin or dibutyl sebacate.

15 . The enrobed gastric residence dosage form of claim 1 , wherein the second coating on the first coating enrobing the gastric residence system comprises a hydration aid comprising at least one of a polyvinylpyrrolidone, a vinylpyrrolidone-vinyl acetate copolymer, a polyethylene glycol, mannitol, or hydroxypropyl methylcellulose.

16 . The enrobed gastric residence dosage form of claim 1 , wherein the enrobed gastric residence dosage form allows the gastric residence system in the folded configuration to assume an open configuration in at least 20 minutes when exposed to an aqueous pH 7.0 environment.

17 . The enrobed gastric residence dosage form of claim 1 , wherein the enrobed gastric residence dosage form allows the gastric residence system in the folded configuration to assume an open configuration in less than 20 minutes when exposed to an aqueous pH 3.0 environment.

18 . The enrobed gastric residence dosage form of claim 1 , wherein the enrobed gastric residence dosage form is used to treat a human.

Assignments (5)

Continuity (2)

References Cited (133)